SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) October 30, 2000


                                   ENZON, INC.
             (Exact name of registrant as specified in its charter)


          Delaware                    0-12957                  22-237286
(State or other jurisdiction        (Commission              (IRS Employer
     of incorporation)              File Number)             Identification)


                20 Kingsbridge Road, Piscataway, New Jersey 08854
               (Address of principal executive offices) (Zip Code)


        Registrant's telephone number, including area code (732) 980-4500


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)




Item 5. Other Events

Enzon   Announces   Schering-Plough   Reports   Results  of  Phase  III  Pivotal
PEG-INTRON(TM) PLUS REBETOL(R) Study

     Enzon, Inc. announced today that  Schering-Plough  Corporation reported the
results of a pivotal Phase III clinical  study,  presented for the first time at
the  Presidential  Plenary  Session of the 51st Annual  Meeting of the  American
Association for the Study of Liver Diseases (AASLD) in Dallas.  The study showed
that combination therapy with once-weekly PEG-INTRON(TM) (peginterferon alfa-2b)
Injection plus daily REBETOL(R) (Ribavirin, USP) Capsules achieved a 54% rate of
sustained virologic response overall in previously untreated adult patients with
chronic  hepatitis C.  Sustained  virologic  response  across  hepatitis C virus
genotypes ranged from 42% to 82% in patients  receiving  PEG-INTRON plus REBETOL
combination therapy. When analyzed on an optimized dose/body-weight basis (>10.6
mg/kg of REBETOL daily), sustained virologic response was 61% for all genotypes,
48% for genotype 1 and 88% for genotypes 2 and 3.  PEG-INTRON is a longer-acting
form of  INTRON A that  uses  proprietary  PEG  technology  developed  by Enzon.
Sustained virologic response (SVR) is defined as sustained loss of detectable(1)
hepatitis C virus (HCV-RNA).

     Results of the PEG-INTRON plus REBETOL study represent the largest and most
complete  clinical data reported to date involving  peginterferon  and ribavirin
combination  therapy. In all, PEG- INTRON was the subject of seven presentations
by study investigators at AASLD.

PEG-INTRON Plus REBETOL Combination Therapy

     In an AASLD Presidential  Plenary Session,  study  investigators  presented
results of a pivotal Phase III clinical study designed to establish the activity
and  tolerance of two dosing  regimens of  PEG-INTRON  plus REBETOL  compared to
REBETRON(TM)  Combination Therapy containing REBETOL  (Ribavirin,  USP) Capsules
and  INTRON(R)  A  (Interferon  alfa-2b,  recombinant)  Injection,  the  current
standard of care, in previously  untreated chronic hepatitis C patients. A total
of 1,530  patients  from 62 sites  worldwide  (33 U.S., 5 Canada,  22 Europe,  2
Other) were randomized to three treatment arms:

(A)  PEG-INTRON  Injection 1.5 mcg/kg once weekly (QW) plus REBETOL Capsules 800
     mg/daily for 48 weeks (PEG 1.5/R);
(B)  PEG-INTRON  1.5 mcg/kg QW plus  REBETOL  1000-1200  mg/daily for four weeks
     followed by PEG-INTRON 0.5 mcg/kg QW plus REBETOL 1000-1200 mg/daily for 44
     weeks (Peg 0.5/R); or

- ----------

     (1)  Defined as HCV-RNA  below limit of  detection  using a  research-based
          RT-PCR assay.


                                       2



(C)  INTRON A Injection 3 MIU/three times weekly plus REBETOL Capsules 1000-1200
     mg/daily for 48 weeks (REBETRON).

     The  demographic/disease  characteristics  of  patients  in this study were
similar to those in previous  Schering-Plough  hepatitis C registration studies:
66% male; mean age 44 years; mean body weight 83 kg,  pretreatment  HCV-RNA (NGI
LLQ 100 copies/ml)>2  million copies 68%; and HCV genotype 1 (68%),  genotypes 2
and 3 (29%), other genotypes (3%) (InnoLipa, Innogenetics).

     Patients  in the PEG  1.5/R arm  achieved  significantly  higher  SVR (54%)
overall  compared to patients in the REBETRON arm (47%),  while  patients in the
PEG  0.5/R  arm  achieved  numerically  similar  SVR  (47%) to  those  receiving
REBETRON.  When  analyzed on a  dose/body-weight  basis  (>10.6 mg/kg of REBETOL
daily),  SVR was 61% overall for patients in the PEG 1.5/R arm,  compared to 48%
for patients in the PEG 0.5/R arm and 47% for patients in the REBETRON arm.

     Consistent with previous studies, the rates of sustained virologic response
in this study were  greatly  influenced  by genotype,  with  patients in the PEG
1.5/R arm with  genotype  1, the  predominant  genotype  worldwide  and the most
difficult  to treat,  achieving  42% SVR compared to 34% and 33% for patients in
the  PEG  0.5/R  arm  and  REBETRON  arm,  respectively.   When  analyzed  on  a
dose/body-weight basis (>10.6 mg/kg of REBETOL daily), patients in the PEG 1.5/R
arm with  genotype 1 achieved  48% SVR  compared to 34% for patients in both the
PEG 0.5/R arm and the REBETRON  arm.  Patients  with  genotypes 2 and 3 in these
treatment arms achieved 88%, 80% and 80% SVR, respectively.

     The safety profile of both doses of PEG-INTRON  plus REBETOL was similar to
that for REBETRON, with no new types of adverse events observed. Discontinuation
of therapy for adverse  events was similar in all three  treatment  groups:  PEG
1.5/R (14%), PEG 0.5/R (13%),  REBETRON (13%), as was dose  modifications,  42%,
36%, and 34%, respectively.


                                       3



                 PEG-INTRON PLUS REBETOL PIVOTAL PHASE III STUDY

                         (Sustained Virologic Response)


- --------------------------------------------------------------------------------------------- RESULTS: (A) PEG 1.5/R (B) PEG 0.5/R (C) REBETRON A vs. C - --------------------------------------------------------------------------------------------- SVR (overall) 54% 47% 47% p=0.01 - --------------------------------------------------------------------------------------------- SVR Genotype 1 42% 34% 33% p=0.02 - --------------------------------------------------------------------------------------------- SVR Genotypes 2&3 82% 80% 79% - --------------------------------------------------------------------------------------------- Optimized Weight-Based Dosing - ----------------------------- (>10.6 mg/kg/daily REBETOL*) - --------------------------------------------------------------------------------------------- SVR (overall) 61% 48% 47% - --------------------------------------------------------------------------------------------- SVR Genotype 1 48% 34% 34% - --------------------------------------------------------------------------------------------- SVR Genotypes 2 & 3 88% 80% 80% - ---------------------------------------------------------------------------------------------
PEG-INTRON Additional PEG-INTRON presentations at AASLD included a study showing that treatment with PEG-INTRON resulted in higher rates of sustained virologic response in Black and Hispanic patients compared to standard alpha interferon therapy. Another study with PEG-INTRON showed that sustained virologic response is associated with marked improvement in hepatic inflammation and fibrosis, and also showed that patients who do not achieve a sustained response, i.e. those who relapse following treatment or who are nonresponders, also show improvement in hepatic fibrosis. Study investigators suggested that further evaluation is warranted to determine whether some patients may benefit from maintenance therapy with PEG-INTRON. A study presented by John B. Wong, M.D., Tufts University, New England Medical Center, Boston, Mass., estimated the cost-effectiveness of PEG-INTRON plus REBETOL for a range of possible trial outcomes as compared to REBETRON Combination Therapy or no antiviral therapy. In his study, Wong concluded that if trial results suggest that PEG-INTRON plus REBETOL increases the relative rate of sustained virologic response, then 48 weeks of combination therapy with PEG-INTRON plus REBETOL should provide good value for its clinical benefit. 4 Except for the historical information herein, the matters discussed herein include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors which are described in the Company's Form 10-K, Form 10-Qs and Form 8-K on file with the SEC, including without limitation, risks in obtaining and maintaining regulatory approval for expanded indications, market acceptance of and continuing demand for Enzon's products and the impact of competitive products and pricing. 5 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 2, 2000 ENZON, INC. ---------------------- (Registrant) By: /S/ KENNETH J. ZUERBLIS ------------------------- Kenneth J. Zuerblis Vice President, Finance and Chief Financial Officer 6